Figure 2
From: Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library
Validation of inhibition effects of selected compounds on CK2 kinase activity and structures of compounds. A. Inhibition effects of selected compounds on CK2 kinase activity was validated by radioisotope kinase assay at a concentration of 10 μM compound using 10 μM ATP. TBB is the positive control. Ck2 kinase activity is represented as relative CK2 activity to controls (DMSO). Data represents the average of duplicate experiments and bars indicate SD.4A3: hematein. B. Structure of compounds: 4A3 (hematein): 3, 4, 10, 6a-tetrahydroxy-7, 6a-dihydroindeno [2, 1-c] chroman-9-one MW 300.26, CAS No. 15489-90-4; 4A6: 5-methoxyfurano [3,2-g]chromen-2-one; 4A9: 4-hydroxy-3-{2- [8-hydroxy-7-(hydroxymethyl)-1,7-dimethyl-3-methylenebicyclo[4. 4.0]dec-2-yl]ethylidene}-4,5-dihydrofuran-2-one.